Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis
Existing randomised controlled trials use a variety of definitions for PPF with eligibility criteria that have limited representativeness. Forced vital capacity decline and transplant-free survival vary according to trial eligibility and interstitial lung disease subtypes.
Authors
- H. Manganas
- Christopher J. Ryerson (ORCID: https://orcid.org/0000-0003-1049-393X)
- Kerri A. Johannson (ORCID: https://orcid.org/0000-0003-1205-5511)
- Yet Hong Khor (ORCID: https://orcid.org/0000-0002-5434-9342)
- Nasreen Khalil (ORCID: https://orcid.org/0000-0001-5372-6858)
- Deborah Assayag (ORCID: https://orcid.org/0000-0002-2497-9984)
- Néstor L. Müller (ORCID: https://orcid.org/0000-0002-0657-8175)
- Veronica Marcoux
- Jolene H. Fisher
- Martin Kolb (ORCID: https://orcid.org/0000-0003-3837-1467)
- Daniel-Costin Marinescu
Institutions
- University of British Columbia (CA)
- The University of Melbourne (AU)
- University of Calgary (CA)
- University of Toronto (CA)
- St. Paul's Hospital (CA)
- University of Saskatchewan (CA)
- Monash Alfred Psychiatry Research centre (AU)
- Institute for Breathing and Sleep (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- Austin Health (AU)
- McGill University (CA)
- Monash University (AU)
- McMaster University (CA)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1183/13993003.01575-2024
- Citations
- 5
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Boehringer Ingelheim
- National Health and Medical Research Council